Non-GLP-1 peptides like AOD 9604, Tesamorelin, and CJC-1295/Ipamorelin target fat metabolism and growth hormone rather than appetite suppression
However, this approach poses greater challenges for labs using LC-MS for the IGF-1 assay
Native rhIGF-1 (mecasermin, brand name Increlex) is FDA-approved only for the long-term treatment of growth failure in pediatric patients with severe primary IGF-1 deficiency or with GH gene deletion who have developed neutralizing antibodies to GH
At 15 units/week, one vial covers ~13 weeks of maintenance
Resistance training does not need to be high-volume to produce meaningful results when paired with tesamorelin
As free CORT measurements were not feasible, levels of free plasma CORT were estimated based on plasma total cortisol, CBG and albumin concentrations with the following calculation [relative plasma total corticosterone0.85*relative plasma CBG*relative plasma total corticosterone)(0.10*relative plasma albumin*relative plasma total corticosterone)]